Insmed Incorporated 2017 Investor Presentation

Insmed Incorporated presents clinical pipeline progress including Phase 3 CONVERT trial data expected for ARIKAYCE in nontuberculous mycobacteria lung disease with planned accelerated US approval filing. The company outlines strategy to commercialize ARIKAYCE independently in US, Europe, and Japan, while advancing INS1007 for multiple indications and INS1009 for pulmonary arterial hypertension.